SelectX is an emerging biopharmaceutical company focused on the discovery and development of aminoglycoside therapeutics for unmet medical needs. SelectX has built the industry’s most advanced aminoglycoside drug discovery platform and is leveraging it to develop novel best-in-class and first-in-class compounds for antiinfective and other therapeutic applications.

The company’s most advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs).  SXP2523 possesses broad spectrum coverage with excellent potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus.

SelectX is also developing a next generation inhaled aminoglycoside antibiotic for drug resistant gram-negative infections in patients with Cystic Fibrosis (CF) and other respiratory diseases.

In addition to its antimicrobial programs, SelectX has efforts underway to identify and optimize non-antibiotic aminoglycoside (naAG) leads for discovery programs targeting key pathways including cell migration, calcium channels, metalloproteinases, nonsense mutation correction, and antivirals .

SelectX Pharmaceuticals, Inc.
One Innovation Drive
Worcester, MA  01605
Phone: (508) 798-0216
Fax: (508) 798-0217